DEMAND FOR VALUE BASED PHARMACEUTICALS INCREASING IN CHINA
August 1st, 2014
THE PHARMACEUTICALS sector has not emerged unscathed from China’s recent anti-trust investigations of multinational companies, but with healthcare spending rising, there are plenty of opportunities for the industry. The powerful National Development and Reform Commission (NDRC), which investigates alleged price fixing in China, has made claims alleging GlaxoSmithKline (GSK) have charged Chinese consumers seven times its average global prices.Such crackdowns look set to become the norm and have refocused minds on the potential for sales in China, whose ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.